<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacy (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacy (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmacy</journal-id><journal-title-group><journal-title>Pharmacy</journal-title></journal-title-group><issn pub-type="epub">2226-4787</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407506</article-id><article-id pub-id-type="pmc">PMC12101423</article-id>
<article-id pub-id-type="doi">10.3390/pharmacy13030068</article-id><article-id pub-id-type="publisher-id">pharmacy-13-00068</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Preferences of Hospital Pharmacists for the Different Attributes of Intravitreal Treatments for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Spain: The SEEKING Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1800-6198</contrib-id><name><surname>Poveda</surname><given-names>Jos&#x000e9; Luis</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmacy-13-00068" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Arn&#x000e1;iz</surname><given-names>Pablo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-pharmacy-13-00068" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez</surname><given-names>Silvia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-pharmacy-13-00068" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>Bel&#x000e9;n</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-pharmacy-13-00068" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7348-7337</contrib-id><name><surname>Fern&#x000e1;ndez-Ferreiro</surname><given-names>Anxo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-pharmacy-13-00068" ref-type="aff">3</xref><xref rid="af4-pharmacy-13-00068" ref-type="aff">4</xref><xref rid="c1-pharmacy-13-00068" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Mestres</surname><given-names>Conxita</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmacy-13-00068"><label>1</label>Hospital La F&#x000e9;, 46026 Valencia, Spain; <email>poveda_josand@gva.es</email></aff><aff id="af2-pharmacy-13-00068"><label>2</label>Roche Farma S.A., 28042 Madrid, Spain; <email>pablo.arnaiz@roche.com</email> (P.A.); <email>silvia.lopez.sl4@roche.com</email> (S.L.); <email>belen.munoz_molina@roche.com</email> (B.M.)</aff><aff id="af3-pharmacy-13-00068"><label>3</label>Pharmacy Department, University Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain</aff><aff id="af4-pharmacy-13-00068"><label>4</label>FarmaCHUSLab, Health Research Institute Santiago Compostela (IDIS), 15706 Santiago de Compostela, Spain</aff><author-notes><corresp id="c1-pharmacy-13-00068"><label>*</label>Correspondence: <email>anxordes@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>13</volume><issue>3</issue><elocation-id>68</elocation-id><history><date date-type="received"><day>07</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>09</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The process of evaluation and selection of drugs in Spain is currently changing, with hospital pharmacists (HPs) having a growing relevance. This cross-sectional observational study aimed to assess HPs&#x02019; preferences for different hypothetical intravitreal treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Best corrected visual acuity (BCVA), ocular adverse events (AE), annual drug cost, available presentation, and mechanisms of action (MoA) were the selected attributes. A conjoint analysis was used. Ninety-one HPs completed the study. The mean (SD) age was 39.2 (10.2) years, 60.4% were female, and the mean (SD) time of experience as HP was 12.6 (8.3) years. For nAMD treatments, BCVA (38.6%) and ocular AE (27.3%) were the most important attributes, while annual drug cost (16.3%), available presentation (11.1%), and MoA (6.7%) were not as important. For DME drugs, BCVA (44.6%) and ocular AE (25.5%) were the most significant factors; annual drug cost (17.9%), the drug&#x02019;s available presentation (7.3%), and MoA (4.8%) were not considered to be as crucial. Preferences were comparable independent of HP experience. Effectiveness and safety were the most important attributes when choosing a drug. Comprehending the significant characteristics for HPs could potentially improve their collaborative function within multidisciplinary teams involved in intravitreal treatments.</p></abstract><kwd-group><kwd>conjoint analysis</kwd><kwd>diabetic macular edema</kwd><kwd>hospital pharmacists</kwd><kwd>intravitreal treatment</kwd><kwd>neovascular age-related macular degeneration</kwd><kwd>preferences</kwd></kwd-group><funding-group><award-group><funding-source>Roche Farma S.A.</funding-source></award-group><funding-statement>This research was funded by Roche Farma S.A. The APC was funded by Roche Farma S.A.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmacy-13-00068"><title>1. Introduction</title><p>It may be noted here that age-related macular degeneration (AMD) and diabetic macular edema (DME) are frequent retinal degenerative diseases and are responsible for the majority of cases of blindness due to retinal disease [<xref rid="B1-pharmacy-13-00068" ref-type="bibr">1</xref>]. AMD and DME are expected to increase in prevalence in the coming years due to the aging of the population [<xref rid="B2-pharmacy-13-00068" ref-type="bibr">2</xref>,<xref rid="B3-pharmacy-13-00068" ref-type="bibr">3</xref>,<xref rid="B4-pharmacy-13-00068" ref-type="bibr">4</xref>,<xref rid="B5-pharmacy-13-00068" ref-type="bibr">5</xref>]. Thus, early diagnosis and rapid treatment onset are essential to achieve the best results and preserve vision [<xref rid="B5-pharmacy-13-00068" ref-type="bibr">5</xref>,<xref rid="B6-pharmacy-13-00068" ref-type="bibr">6</xref>,<xref rid="B7-pharmacy-13-00068" ref-type="bibr">7</xref>].</p><p>AMD is a chronic, progressive, and severe disease characterized by degenerative alterations in the central retina, which constitutes the main cause of severe visual impairment and irreversible blindness in elderly people in developed countries [<xref rid="B8-pharmacy-13-00068" ref-type="bibr">8</xref>,<xref rid="B9-pharmacy-13-00068" ref-type="bibr">9</xref>]. The overall prevalence of AMD is estimated to be approximately 8.7% worldwide, although with substantial variations among different populations [<xref rid="B5-pharmacy-13-00068" ref-type="bibr">5</xref>]. According to the World Health Organization (WHO), about 196 million people are affected around the world, with the overall incidence of AMD increasing from 4.2% in patients aged 45&#x02013;49 years to 27.2% in those aged 80&#x02013;85 years [<xref rid="B10-pharmacy-13-00068" ref-type="bibr">10</xref>]. In the European Union, approximately 67 million people are currently affected by any form of AMD, and this number is expected to increase to 77 million by 2050 [<xref rid="B4-pharmacy-13-00068" ref-type="bibr">4</xref>]. The most severe form of AMD is neovascular AMD (nAMD), responsible for 90% of the severe vision loss associated with AMD [<xref rid="B8-pharmacy-13-00068" ref-type="bibr">8</xref>,<xref rid="B11-pharmacy-13-00068" ref-type="bibr">11</xref>].</p><p>DME is a multifactorial and complex disease characterized by exudative fluid accumulation in the macula, and it is the main cause of blindness among patients with diabetes mellitus (DM) [<xref rid="B12-pharmacy-13-00068" ref-type="bibr">12</xref>,<xref rid="B13-pharmacy-13-00068" ref-type="bibr">13</xref>]. The prevalence of DME among individuals with DM in Europe was estimated to be 3.7%, with a mean annual incidence of 0.5% [<xref rid="B3-pharmacy-13-00068" ref-type="bibr">3</xref>].</p><p>Currently, there are many treatments available for these retinopathies, mainly anti-vascular endothelial growth factor (anti-VEGF) agents for nAMD and anti-VEGF or corticosteroids for DME [<xref rid="B14-pharmacy-13-00068" ref-type="bibr">14</xref>,<xref rid="B15-pharmacy-13-00068" ref-type="bibr">15</xref>]. While the drug effectiveness remains the most valuable characteristics, treatment choice considers other aspects (safety, cost, etc.), and different stakeholders (patients, doctors, and hospital pharmacists [HP]) influence medical decision-making while assessing the treatment characteristics in a different way [<xref rid="B16-pharmacy-13-00068" ref-type="bibr">16</xref>,<xref rid="B17-pharmacy-13-00068" ref-type="bibr">17</xref>]. HP are especially relevant in selecting treatments for conditions such as intravitreal treatments and providing support to decision- making [<xref rid="B17-pharmacy-13-00068" ref-type="bibr">17</xref>,<xref rid="B18-pharmacy-13-00068" ref-type="bibr">18</xref>].</p><p>Elicitation of preferences is a method used to evaluate the significance that individuals attribute to various features of a specific product. This approach has been employed to comprehend the importance that stakeholders place on the diverse characteristics of medical interventions [<xref rid="B19-pharmacy-13-00068" ref-type="bibr">19</xref>,<xref rid="B20-pharmacy-13-00068" ref-type="bibr">20</xref>]. Preferences for elicitation using conjoint analysis (CA) techniques have been successfully applied to assess for preferences in different settings [<xref rid="B18-pharmacy-13-00068" ref-type="bibr">18</xref>,<xref rid="B21-pharmacy-13-00068" ref-type="bibr">21</xref>,<xref rid="B22-pharmacy-13-00068" ref-type="bibr">22</xref>]. CA is a technique based on mathematical psychology and Lancaster&#x02019;s theory of value that aims to identify the value that subjects assign to different attributes of a given product [<xref rid="B23-pharmacy-13-00068" ref-type="bibr">23</xref>]. CA presents individuals with a series of hypothetical product profiles, each characterized by a set of attributes and levels for each attribute. Its rationale is that it closely resembles the everyday decisions individuals make when choosing between alternatives with multiple attributes, and it has been used to assess the preferences of different healthcare professionals [<xref rid="B16-pharmacy-13-00068" ref-type="bibr">16</xref>,<xref rid="B18-pharmacy-13-00068" ref-type="bibr">18</xref>,<xref rid="B23-pharmacy-13-00068" ref-type="bibr">23</xref>,<xref rid="B24-pharmacy-13-00068" ref-type="bibr">24</xref>].</p><p>Currently, in Spain, there is an ongoing paradigm shift in drug evaluation and selection. This shift is associated with the growing relevance of clinical decision-making based on values and the important role that HPs have in therapeutic choices. The current research intends to evaluate HPs&#x02019; preferences for different hypothetical intravitreal treatments for nAMD and DME, according to a set of selected attributes, to quantify the weight of each studied attribute. As a secondary objective, this study aims to assess whether the preferences are comparable at different levels of clinical experience.</p></sec><sec id="sec2-pharmacy-13-00068"><title>2. Materials and Methods</title><sec sec-type="subjects" id="sec2dot1-pharmacy-13-00068"><title>2.1. Study Design and Participants</title><p>The SEEKING study is a cross-sectional observational study that aims to understand the HPs&#x02019; preferences among different attributes of hypothetical intravitreal treatments for nAMD and DME. HPs actively involved in the management of intravitreal treatments of patients with nAMD or DME were invited to participate in the study via email from July to October 2023. The study was approved by the Research Ethics Board of Hospital Cl&#x000ed;nico San Carlos (code number: 23/307-E). Due to the particular nature of the data collected (not patient data, but opinions/points of view of participants), and in compliance with regulatory requirements, HPs were informed about the study objectives and the confidentiality and preservation of their responses. Participants provided informed consent before the start of the study.</p></sec><sec id="sec2dot2-pharmacy-13-00068"><title>2.2. Variables</title><p>The present CA was not related to any medicinal product or treatment. No data from patients were collected either individually or collectively, and the study subjects were HPs, so only variables related to them were collected.</p><p>The CA evaluated eight hypothetical treatment scenarios with different combinations of attributes and levels of assessment, which were presented to the HPs to rank them according to their preferences. Two independent preferences exercises were presented, one for nAMD and one for DME, including the same attributes for each hypothetical treatment, but with different levels for each attribute. To determine the scenarios, two steps were carried out, as follows:<list list-type="order"><list-item><p>Selection of attributes and levels (<xref rid="app1-pharmacy-13-00068" ref-type="app">Supplementary Table S1</xref>) [<xref rid="B25-pharmacy-13-00068" ref-type="bibr">25</xref>]: Five treatment attributes, including best corrected visual acuity (BCVA), ocular adverse events (AE), annual drug cost, available presentation, and mechanism of action (MoA), were selected from those used in clinical trials and other studies, extracted from a literature review, and after consensus of an expert panel of HPs, and also determined by a consensus of the most relevant levels for each attribute.</p></list-item><list-item><p>Application of an orthogonal design with Statistical Package for the Social Sciences (SPSS): The five attributes with two levels each (nAMD) and the five attributes, four of them with two levels and one with three levels (DME) defined in step 1 (<xref rid="app1-pharmacy-13-00068" ref-type="app">Supplementary Table S1</xref>), were used. The maximum number of possible scenarios was 32 for nAMD and 48 for DME. Since it is impossible to establish a ranking among all these possibilities at a cognitive level, eight scenarios (cards from A to H) were selected by applying an orthogonal design with SPSS. HPs&#x02019; preferences for the final eight scenarios were evaluated with a ranking system (<xref rid="app1-pharmacy-13-00068" ref-type="app">Supplementary Table S2</xref>).</p></list-item></list></p><p>In addition, participants answered questions related to their sociodemographic and professional practice characteristics as secondary variables.</p></sec><sec id="sec2dot3-pharmacy-13-00068"><title>2.3. Analysis</title><p>The main analysis was focused on the preferences of HPs for several attributes of intravitreal treatments. Ordinary least squares (OLS) regression was selected in the current research to estimate parameters. From the part-worth, CA calculates the relative importance that individuals assign to the different attributes that make up each hypothetical treatment. Attribute importance is the difference between their highest and lowest utility levels. If the distance between the utility levels of an attribute is large, that attribute has a larger bearing on the respondents&#x02019; choice of treatment than another one where the distance is not as large. The relative importance of each attribute was obtained by dividing its individual importance by the sum of all. The most important attribute is the one whose levels are extreme in terms of utilities.</p><p>To assess if preferences were comparable among different levels of clinical experience, a preference analysis was divided into two groups depending on the distribution of years in managing intravitreal treatment. The categorization was established according to the median time obtained in the sample:<list list-type="order"><list-item><p>Some experience (&#x02264;5 years): Years of experience in managing intravitreal treatments for nAMD/DME equal to or less than the median time obtained in the study sample.</p></list-item><list-item><p>Broad experience (&#x0003e;5 years): Years of experience in managing intravitreal treatments for nAMD/DME higher than the median time obtained in the study sample.</p></list-item></list></p></sec><sec id="sec2dot4-pharmacy-13-00068"><title>2.4. Sample Size and Statistical Analysis</title><p>Sample size was estimated based on the minimum number of subjects needed to set the exercise of preferences, considering that eight theoretical scenarios would be presented to the HPs. Since a regression model would be built with their answers, a minimum of ten observations per scenario was required (i.e., 80 HP). To ensure the expected minimum sample of 80 complete questionnaires, a participation of 100 HPs was estimated. Finally, the valid participation of 91 HPs was obtained, thus exceeding the minimum necessary sample.</p><p>Descriptive statistics were presented for all variables. Continuous variables were analyzed with measures of central tendency (mean and median), variability/dispersion (standard deviation [SD], interquartile ranges, and minimum and maximum), and categorical variables with distributions of absolute and relative frequencies (percentages of groups).</p><p>All statistical hypotheses were contrasted against bilateral alternatives and with a significance level of 5%. No adjustments for multiple comparisons or multiple analyses were performed. The statistical analysis was performed using SPSS version 19.0 and Statistical Analysis Software (SAS) Enterprise Guide version 7.15. SPSS uses the algorithm OLS to estimate profits.</p></sec></sec><sec sec-type="results" id="sec3-pharmacy-13-00068"><title>3. Results</title><p>A total of 118 HPs were registered: 98 completed the selection criteria and 91 completed the two preferences exercises. The mean (SD) age was 39.2 (10.2) years, 60.4% were female, and the mean (SD) time of experience as a HP was 12.6 (8.3) years, with a median of 10 years. Only in two cases (2.2%) was the experience &#x0003c; 1 year. A total of 83 (91.2%) HPs stated more than one year of experience in managing intravitreal treatments, with 7.4 (5.0) years being their mean time of experience. The main characteristics of the study population are shown in <xref rid="pharmacy-13-00068-t001" ref-type="table">Table 1</xref>.</p><sec id="sec3dot1-pharmacy-13-00068"><title>3.1. HPs&#x02019; Preferences for the Different Attributes of Intravitreal Treatments</title><p>In the nAMD exercise, scenario G (improvement &#x02265; 15 letters, mild but more frequent AE, no effect/decrease annual drug cost, prefilled syringe presentation, and MoA with less spacing between doses) was the most preferred treatment scenario (76.9% of HPs selected this scenario as the most preferred one). In contrast, the least preferred (85.7% of HPs) was scenario D (improvement &#x0003c; 15 letters, severe but less frequent AE, annual drug cost increase, vial presentation, and MoA with less spacing between doses) (<xref rid="pharmacy-13-00068-f001" ref-type="fig">Figure 1</xref>).</p><p>In the DME exercise, the most preferred treatment scenario (58.2% of HPs) was scenario B (improvement &#x02265; 15 letters, mild but more frequent AE, no effect/decrease annual drug cost, vial presentation, and MoA with more spacing doses). In contrast, scenario G (improvement &#x0003c; 15 letters, severe but less frequent AE, annual drug cost increase, vial presentation, and MoA with less spacing between doses) was the least preferred (80.2% of HPs selected them as the least preferred) (<xref rid="pharmacy-13-00068-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec3dot2-pharmacy-13-00068"><title>3.2. Utility Scores and Importance</title><p><xref rid="pharmacy-13-00068-t002" ref-type="table">Table 2</xref> describes the estimated utilities reported by HPs for attributes and levels assessed in hypothetical treatment scenarios. In both exercises, HPs showed a greater preference for treatment scenarios with high effectiveness in terms of BCVA, no effect on annual drug cost, more spacing between doses, and treatments with frequent mild AEs rather than infrequent serious AEs. In terms of treatment presentations, HPs showed a greater preference for prefilled syringes (<xref rid="pharmacy-13-00068-t002" ref-type="table">Table 2</xref>). Utilities obtained were consistent with the information collected at each attribute level, where desired levels of attributes offer greater utilities. Pearson&#x02019;s R and Kendall&#x02019;s &#x003c4; coefficients showed high correlations: between 0.998 (<italic toggle="yes">p</italic> &#x0003c; 0.001) and 1.000 (<italic toggle="yes">p</italic> &#x0003c; 0.001) for nAMD and 0.991 (<italic toggle="yes">p</italic> &#x0003c; 0.001) and 1.000 for DME, respectively.</p><p>For intravitreal treatments for nAMD, participants placed the greatest relative importance on BCVA (38.6%), followed by ocular AE (27.3%), annual drug cost (16.3%), available presentation (11.1%), and MoA (6.7%) (<xref rid="pharmacy-13-00068-t002" ref-type="table">Table 2</xref>). The importance assigned to each attribute showed minor differences according to the method used (average or relative importance).</p><p>For the DME exercise, according to relative importance, the most important attribute for an intravitreal treatment was BCVA (44.6%), followed by ocular AE (25.5%), annual drug cost (17.9%), available presentation (7.3%), and MoA (4.8%). Average importance, obtained at the HP level, was similar but not equal in order in the last attributes: BCVA (34.5%), followed by ocular AE (25.1%), available presentation (15.5%), annual drug cost (15.4%), and MoA (9.5%) (<xref rid="pharmacy-13-00068-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec3dot3-pharmacy-13-00068"><title>3.3. HPs&#x02019; Preferences According to Clinical Experience</title><p>HPs were stratified and analyzed into two different groups according to their previous experience in managing intravitreal treatments for nAMD/DME: 48 HPs with experience of &#x02264;5 years (some experience; 52.7%) and 43 with &#x02265;5 years of experience (broad experience; 47.3%). Higher and lower rankings were similar in both groups. In the nAMD exercise, a difference in ranking was observed in scenario F, while in the DME exercise, it was observed in scenarios A and B (<xref rid="pharmacy-13-00068-f002" ref-type="fig">Figure 2</xref>).</p><p>As previously observed in the global analysis, in the nAMD exercise, scenario G was the most preferred by 83.3% of HPs with some experience and by 69.8% of HPs with broad experience, while scenario D was the least preferred in the two groups (91.7% and 79.1%, respectively). Likewise, in the DME exercise, scenario B was the most preferred by 45.8% of HPs with some experience and by 72.1% of HPs with broad experience, while scenario G was the least preferred in the two groups (83.3% and 76.7%, respectively).</p><p>Both groups showed a greater preference for treatment scenarios with high efficacy and safety in terms of BCVA (&#x02265;15 letters) and mild frequent AEs, in addition to no increase in cost. In terms of treatment administrations for nAMD, HPs showed a greater preference for prefilled syringes and more spacing between doses. For DME, HPs with some experience preferred prefilled syringes followed by an implant and vial, while HPs with broad experience preferred prefilled syringes followed by a vial and implant (<xref rid="pharmacy-13-00068-t003" ref-type="table">Table 3</xref>).</p><p>In the nAMD exercise, HPs with some experience managing intravitreal treatments showed a greater preference for treatments with higher BCVA effectiveness (relative importance: 41.1%). Furthermore, they placed greater importance on ocular AE (25.2%), annual drug cost (15.9%), and available presentation (13.6%), while giving lower importance to MoA (4.2%). On the other hand, HPs with broad experience showed a greater preference for treatments with higher BCVA effectiveness (35.8%), greater importance on ocular AE (29.7%), and annual drug cost (16.8%), as well as similar importance between MoA (9.6%) and available presentation (8.2%) (<xref rid="pharmacy-13-00068-t003" ref-type="table">Table 3</xref>).</p><p>In the DME exercise, the order of importance was the same among HPs with some experience and broad experience, although the group with broad experience assigned a similar importance to available presentation and MoA, giving greater importance to effectiveness and AE (<xref rid="pharmacy-13-00068-t003" ref-type="table">Table 3</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-pharmacy-13-00068"><title>4. Discussion</title><p>nAMD and DME are two chronic diseases that can progress and lead to blindness within a few years [<xref rid="B8-pharmacy-13-00068" ref-type="bibr">8</xref>,<xref rid="B9-pharmacy-13-00068" ref-type="bibr">9</xref>,<xref rid="B11-pharmacy-13-00068" ref-type="bibr">11</xref>,<xref rid="B12-pharmacy-13-00068" ref-type="bibr">12</xref>,<xref rid="B13-pharmacy-13-00068" ref-type="bibr">13</xref>,<xref rid="B26-pharmacy-13-00068" ref-type="bibr">26</xref>]. Although current treatments make it possible to delay the progression of these diseases and preserve existing vision, there is a growing interest in considering the added value of new therapies, not only based on effectiveness, but also on other characteristics that may be relevant for the different stakeholders [<xref rid="B14-pharmacy-13-00068" ref-type="bibr">14</xref>,<xref rid="B16-pharmacy-13-00068" ref-type="bibr">16</xref>,<xref rid="B17-pharmacy-13-00068" ref-type="bibr">17</xref>,<xref rid="B26-pharmacy-13-00068" ref-type="bibr">26</xref>]. Differences in BCVA, ocular AE, annual drug cost, available presentation, and MoA lead to uncertainty among HPs who manage the intravitreal treatments based on their own experience and patients&#x02019; preferences.</p><p>Decision-making in the selection of a treatment or health intervention is a complex process due to the presence of multiple factors and differing objectives that can influence the optimal decision [<xref rid="B17-pharmacy-13-00068" ref-type="bibr">17</xref>]. This process becomes even more complicated when the opinions of different stakeholders and patient perspectives are considered. Understanding the preferences of each group, even when they may differ, can be crucial in the decision-making process [<xref rid="B16-pharmacy-13-00068" ref-type="bibr">16</xref>,<xref rid="B17-pharmacy-13-00068" ref-type="bibr">17</xref>,<xref rid="B18-pharmacy-13-00068" ref-type="bibr">18</xref>].</p><p>Although there are different estimation procedures in the application of CA techniques to assess preferences [<xref rid="B27-pharmacy-13-00068" ref-type="bibr">27</xref>], OLS regression was selected in the present study to estimate parameters, as it presents major advantages because it produces results that are virtually identical to those obtainable with non-metric procedures, which are more complex from computational point of view.</p><p>The HP collective in Spain has a growing interest in evaluating patients&#x02019; outcomes as the most important consequence of their professional activity, although there are a lack of publications evaluating their treatment preferences in Spain. Only two recent studies were identified: a preferences study in the field of multiple sclerosis [<xref rid="B18-pharmacy-13-00068" ref-type="bibr">18</xref>] and a multicriteria decision analysis (MCDA) for DME treatments with multiple stakeholders, including pharmacists [<xref rid="B17-pharmacy-13-00068" ref-type="bibr">17</xref>]. Mart&#x000ed;nez-L&#x000f3;pez et al. concluded that understanding which treatment characteristics are meaningful to HPs may help to enhance their synergistic role in the multidisciplinary management of patients with multiple sclerosis, although further studies are necessary to gather a more comprehensive spectrum of HP-relevant attributes [<xref rid="B18-pharmacy-13-00068" ref-type="bibr">18</xref>]. De Andr&#x000e9;s-Nogales et al. conducted a MCDA to determine the most relevant criteria to decision-making in the management of DME based on the perspectives of multiple stakeholders in Spain, concluding that, from a multi-stakeholder perspective, the selection of an appropriate DME treatment should guarantee patient safety and maximize visual acuity improvement and treatment effect duration, also contributing to system sustainability by being affordable, having a positive impact on health-related quality of life, and preventing disability [<xref rid="B17-pharmacy-13-00068" ref-type="bibr">17</xref>].</p><p>Our study shows that HPs placed the highest relative importance on BCVA, followed by ocular AE, annual drug cost, available presentation, and MoA, for both exercises, nAMD and DME, with the same conclusion regarding the average importance except for DME exercise, where HP prioritized available presentation over annual drug cost. So, as in other therapeutic areas, such as multiple sclerosis [<xref rid="B18-pharmacy-13-00068" ref-type="bibr">18</xref>], effectiveness and safety are the most relevant attributes.</p><p>Only small differences were found between HPs with some versus broad experience in managing intravitreal treatments for nAMD/DME. In the case of nAMD, differences were observed for scenarios A and G, and, in DME, for scenarios A and B. Both groups (some and broad experience managing intravitreal treatments) showed a greater preference for treatment scenarios with high efficacy and safety in terms of BCVA (&#x02265;15 letters) and mild frequent AEs, in addition to no increase in cost. In terms of treatment administrations for nAMD, HPs with some experience showed a greater preference for prefilled syringes, and those with broad experience preferred more spacing between doses. For DME, HPs with some experience preferred prefilled syringes followed by implants and vials, while those with broad experience preferred prefilled syringes followed by vials and implants.</p><p>There were a few limitations that should be considered while interpreting the outcomes. One possible limitation is inherent to preference elicitation studies, as the preference weights obtained are specific to the attributes and levels of each attribute that are presented, and it is not feasible to include all the attributes and levels that may influence the preferences. A large number of attributes and levels can increase the cognitive difficulty of choice and rank the scenarios, but the inclusion of fewer attributes can omit key attributes [<xref rid="B28-pharmacy-13-00068" ref-type="bibr">28</xref>]. However, the study design phase was conducted to identify and select the final attributes and levels to design the scenarios, and much emphasis was placed on the panel of experts meeting to select only those attributes that they considered most relevant, trying to minimize the number of levels in each one. The second limitation is that, although approximately 2000 HPs experienced in managing intravitreal treatments for nAMD/DME were invited to participate, only 91 (4.6%) who finally accept to participate were considered valid for the present analysis by meeting the selection criteria and having completed the two preference exercises. In any case, the final number of participants is over the minimum needed sample size (80 HPs). Also, this was an exploratory study, and no extrapolation to the total population was planned to be made. Finally, results obtained in the current study must be interpreted considering all attributes and levels used to define scenarios. The importance assigned to each attribute corresponds to relative importance, which is defined according to the importance assigned to one attribute in comparison with all other attributes. Based on that, the importance of specific attributes cannot be interpreted or compared with other studies independently of other attributes used in the study.</p></sec><sec sec-type="conclusions" id="sec5-pharmacy-13-00068"><title>5. Conclusions</title><p>This study describes the use of CA to evaluate HPs&#x02019; preferences for different hypothetical intravitreal treatments with anti-VEGF or corticosteroids for nAMD and DME, according to a set of selected attributes (BCVA, ocular AE, annual drug cost, available presentation, and MoA), and aims to quantify the weight of each studied attribute. Effectiveness and safety were the most important attributes, while cost, available presentation, and MoA were not as important for the HPs when choosing a drug, although &#x0201c;no effect/decrease annual drug cost&#x0201d; was included in the most preferred treatment scenario for both diseases. These preferences were comparable independent of the experience of the HP, although some differences according to the type of hospital and the number of nAMD/DME treatments were observed for the importance given to the available presentation. Understanding which treatment characteristics are meaningful to HPs may help to enhance their synergistic role in the multidisciplinary management of patients with nAMD and DME. Further studies are needed to explore a more comprehensive spectrum of HP-relevant attributes.</p></sec></body><back><ack><title>Acknowledgments</title><p>Medical writing assistance was provided by Pablo Rebollo, M&#x000f3;nica Sarmiento, and Carmen Barrull from IQVIA during the preparation of study protocol and this manuscript. The authors would also like to acknowledge all the hospital Pharmacists who participated in this study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmacy-13-00068"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmacy13030068/s1">https://www.mdpi.com/article/10.3390/pharmacy13030068/s1</uri>, Table S1: Attributes and levels that configure the scenarios; Table S2: Set of preferences scenarios.</p><supplementary-material id="pharmacy-13-00068-s001" position="float" content-type="local-data"><media xlink:href="pharmacy-13-00068-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, A.F.-F. and J.L.P.; methodology, A.F.-F. and J.L.P.; investigation, A.F.-F. and J.L.P.; supervision, P.A., S.L. and B.M.; project administration, P.A., S.L. and B.M.; review, P.A., S.L., B.M., A.F.-F. and J.L.P.; editing, P.A., S.L., B.M., A.F.-F. and J.L.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Research Ethics Board of Hospital Cl&#x000ed;nico San Carlos on 1 June 2023 (code number: 23/307-E).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Jos&#x000e9; Luis Poveda and Anxo Fernandez-Ferreiro have received remuneration for their consultancy work as coordinators of this study and declare no relevant conflicts of interest. Pablo Arn&#x000e1;iz, Silvia L&#x000f3;pez, and Bel&#x000e9;n Mu&#x000f1;oz are employees of Roche Farma Spain.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AE</td><td align="left" valign="middle" rowspan="1" colspan="1">Adverse events</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCVA</td><td align="left" valign="middle" rowspan="1" colspan="1">Best corrected visual acuity</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CA</td><td align="left" valign="middle" rowspan="1" colspan="1">Conjoint analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DME</td><td align="left" valign="middle" rowspan="1" colspan="1">Diabetic macular edema</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HP</td><td align="left" valign="middle" rowspan="1" colspan="1">Hospital pharmacist</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MoA</td><td align="left" valign="middle" rowspan="1" colspan="1">Mechanism of action</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">nAMD</td><td align="left" valign="middle" rowspan="1" colspan="1">Neovascular age-related macular degeneration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SD</td><td align="left" valign="middle" rowspan="1" colspan="1">Standard deviation</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmacy-13-00068"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das</surname><given-names>U.N.</given-names></name>
</person-group><article-title>Diabetic macular edema, retinopathy and age-related macular degeneration as inflammatory conditions</article-title><source>Arch. Med. Sci.</source><year>2016</year><volume>12</volume><fpage>1142</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.5114/aoms.2016.61918</pub-id><pub-id pub-id-type="pmid">27695506</pub-id>
</element-citation></ref><ref id="B2-pharmacy-13-00068"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soriguer</surname><given-names>F.</given-names></name>
<name><surname>Goday</surname><given-names>A.</given-names></name>
<name><surname>Bosch-Comas</surname><given-names>A.</given-names></name>
<name><surname>Bordi&#x000fa;</surname><given-names>E.</given-names></name>
<name><surname>Calle-Pascual</surname><given-names>A.</given-names></name>
<name><surname>Carmena</surname><given-names>R.</given-names></name>
<name><surname>Casamitjana</surname><given-names>R.</given-names></name>
<name><surname>Casta&#x000f1;o</surname><given-names>L.</given-names></name>
<name><surname>Castell</surname><given-names>C.</given-names></name>
<name><surname>Catal&#x000e1;</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@bet.es Study</article-title><source>Diabetologia</source><year>2012</year><volume>55</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1007/s00125-011-2336-9</pub-id><pub-id pub-id-type="pmid">21987347</pub-id>
</element-citation></ref><ref id="B3-pharmacy-13-00068"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.Q.</given-names></name>
<name><surname>Welchowski</surname><given-names>T.</given-names></name>
<name><surname>Schmid</surname><given-names>M.</given-names></name>
<name><surname>Letow</surname><given-names>J.</given-names></name>
<name><surname>Wolpers</surname><given-names>C.</given-names></name>
<name><surname>Pascual-Camps</surname><given-names>I.</given-names></name>
<name><surname>Holz</surname><given-names>F.G.</given-names></name>
<name><surname>Finger</surname><given-names>R.P.</given-names></name>
</person-group><article-title>Prevalence, incidence and future projection of diabetic eye disease in Europe: A systematic review and meta-analysis</article-title><source>Eur. J. Epidemiol.</source><year>2020</year><volume>35</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s10654-019-00560-z</pub-id><pub-id pub-id-type="pmid">31515657</pub-id>
</element-citation></ref><ref id="B4-pharmacy-13-00068"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.Q.</given-names></name>
<name><surname>Welchowski</surname><given-names>T.</given-names></name>
<name><surname>Schmid</surname><given-names>M.</given-names></name>
<name><surname>Mauschitz</surname><given-names>M.M.</given-names></name>
<name><surname>Holz</surname><given-names>F.G.</given-names></name>
<name><surname>Finger</surname><given-names>R.P.</given-names></name>
</person-group><article-title>Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis</article-title><source>Br. J. Ophthalmol.</source><year>2020</year><volume>104</volume><fpage>1077</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2019-314422</pub-id><pub-id pub-id-type="pmid">31712255</pub-id>
</element-citation></ref><ref id="B5-pharmacy-13-00068"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruiz-Moreno</surname><given-names>J.M.</given-names></name>
<name><surname>Arias</surname><given-names>L.</given-names></name>
<name><surname>Abraldes</surname><given-names>M.J.</given-names></name>
<name><surname>Montero</surname><given-names>J.</given-names></name>
<name><surname>Udaondo</surname><given-names>P.</given-names></name>
</person-group><article-title>Economic burden of age-related macular degeneration in routine clinical practice: The RAMDEBURS study</article-title><source>Int. Ophthalmol.</source><year>2021</year><volume>41</volume><fpage>3427</fpage><lpage>3436</lpage><pub-id pub-id-type="doi">10.1007/s10792-021-01906-x</pub-id><pub-id pub-id-type="pmid">34110547</pub-id>
</element-citation></ref><ref id="B6-pharmacy-13-00068"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arias</surname><given-names>L.</given-names></name>
<name><surname>Armad&#x000e1;</surname><given-names>F.</given-names></name>
<name><surname>Donate</surname><given-names>J.</given-names></name>
<name><surname>Garc&#x000ed;a-Arum&#x000ed;</surname><given-names>J.</given-names></name>
<name><surname>Giralt</surname><given-names>J.</given-names></name>
<name><surname>Pazos</surname><given-names>B.</given-names></name>
<name><surname>Pi&#x000f1;ero</surname><given-names>A.</given-names></name>
<name><surname>Mart&#x000ed;nez</surname><given-names>F.</given-names></name>
<name><surname>Mond&#x000e9;jar</surname><given-names>J.J.</given-names></name>
<name><surname>Ortega</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss</article-title><source>Eye</source><year>2009</year><volume>23</volume><fpage>326</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1038/sj.eye.6703053</pub-id><pub-id pub-id-type="pmid">18202712</pub-id>
</element-citation></ref><ref id="B7-pharmacy-13-00068"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rose</surname><given-names>M.A.</given-names></name>
<name><surname>Vukicevic</surname><given-names>M.</given-names></name>
<name><surname>Koklanis</surname><given-names>K.</given-names></name>
<name><surname>Rees</surname><given-names>G.</given-names></name>
<name><surname>Sandhu</surname><given-names>S.</given-names></name>
<name><surname>Itsiopoulos</surname><given-names>C.</given-names></name>
</person-group><article-title>Experiences and perceptions of patients undergoing treatment and quality of life impact of diabetic macular edema: A systematic review</article-title><source>Psychol. Health Med.</source><year>2019</year><volume>24</volume><fpage>383</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1080/13548506.2018.1533249</pub-id><pub-id pub-id-type="pmid">30328707</pub-id>
</element-citation></ref><ref id="B8-pharmacy-13-00068"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garc&#x000ed;a-Layana</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a-Arum&#x000ed;</surname><given-names>J.</given-names></name>
<name><surname>Figueroa</surname><given-names>M.S.</given-names></name>
<name><surname>Arias Barquet</surname><given-names>L.</given-names></name>
<name><surname>Ru&#x000ed;z-Moreno</surname><given-names>J.M.</given-names></name>
<name><surname>Moncl&#x000fa;s-Arbona</surname><given-names>L.</given-names></name>
<collab>The Spanish Amd Multicenter Group</collab>
</person-group><article-title>Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice</article-title><source>J. Ophthalmol.</source><year>2019</year><volume>2019</volume><fpage>9821509</fpage><pub-id pub-id-type="doi">10.1155/2019/9821509</pub-id><pub-id pub-id-type="pmid">31662900</pub-id>
</element-citation></ref><ref id="B9-pharmacy-13-00068"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mond&#x000e9;jar</surname><given-names>J.</given-names></name>
<name><surname>Pellico</surname><given-names>G.</given-names></name>
<name><surname>Sall&#x000e9;n</surname><given-names>T.</given-names></name>
<name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>P.</given-names></name>
<name><surname>Puigcerver</surname><given-names>M.</given-names></name>
<name><surname>Pall&#x000e0;s</surname><given-names>I.</given-names></name>
</person-group><article-title>Management optimization of neovascular age-related macular degeneration in Spain: Evolution towards proactive treatment models</article-title><source>J. Healthc. Qual. Res.</source><year>2023</year><volume>38</volume><fpage>284</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.jhqr.2023.02.007</pub-id><pub-id pub-id-type="pmid">37246110</pub-id>
</element-citation></ref><ref id="B10-pharmacy-13-00068"><label>10.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization (WHO)</collab>
</person-group><article-title>World Report on Vision</article-title><year>2019</year><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/i/item/world-report-on-vision" ext-link-type="uri">https://www.who.int/publications/i/item/world-report-on-vision</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-26">(accessed on 26 June 2024)</date-in-citation></element-citation></ref><ref id="B11-pharmacy-13-00068"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Spanish Eyes Epidemiological (SEE) Study Group</collab>
</person-group><article-title>Prevalence of age-related macular degeneration in Spain</article-title><source>Br. J. Ophthalmol.</source><year>2011</year><volume>95</volume><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1136/bjo.2010.187773</pub-id><pub-id pub-id-type="pmid">21216795</pub-id>
</element-citation></ref><ref id="B12-pharmacy-13-00068"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abreu-Gonzalez</surname><given-names>R.</given-names></name>
<name><surname>Gallego-Pinazo</surname><given-names>R.</given-names></name>
<name><surname>Abraldes</surname><given-names>M.</given-names></name>
<name><surname>Pinilla</surname><given-names>I.</given-names></name>
<name><surname>Lopez-Galvez</surname><given-names>M.I.</given-names></name>
</person-group><article-title>Management of diabetic macular edema patients in clinical practice in Spain</article-title><source>Eur. J. Ophthalmol.</source><year>2019</year><volume>29</volume><fpage>664</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1177/1120672118804079</pub-id><pub-id pub-id-type="pmid">30295076</pub-id>
</element-citation></ref><ref id="B13-pharmacy-13-00068"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fern&#x000e1;ndez-Vigo</surname><given-names>J.I.</given-names></name>
<name><surname>Contreras</surname><given-names>I.</given-names></name>
<name><surname>Crespo</surname><given-names>M.J.</given-names></name>
<name><surname>Beckford</surname><given-names>C.</given-names></name>
<name><surname>Flores-Moreno</surname><given-names>I.</given-names></name>
<name><surname>Cobo-Soriano</surname><given-names>R.</given-names></name>
<name><surname>Pareja</surname><given-names>J.</given-names></name>
<name><surname>Mart&#x000ed;n</surname><given-names>M.D.</given-names></name>
<name><surname>Moreno</surname><given-names>L.</given-names></name>
<name><surname>Arrevola-Velasco</surname><given-names>L.</given-names></name>
</person-group><article-title>Expert Panel Consensus for Addressing Anti-VEGF Treatment Challenges of Diabetic Macular Edema in Spain</article-title><source>Clin. Ophthalmol.</source><year>2022</year><volume>16</volume><fpage>3097</fpage><lpage>3106</lpage><pub-id pub-id-type="doi">10.2147/OPTH.S374763</pub-id><pub-id pub-id-type="pmid">36164581</pub-id>
</element-citation></ref><ref id="B14-pharmacy-13-00068"><label>14.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Sociedad Espa&#x000f1;ola de Retina y V&#x000ed;treo (SERV)</collab>
</person-group><article-title>Gu&#x000ed;as de Pr&#x000e1;ctica Cl&#x000ed;nica y Monograf&#x000ed;as. Gu&#x000ed;a 3: Manejo de las Complicaciones Oculares de la Diabetes</article-title><source>Retinopat&#x000ed;a Diab&#x000e9;tica y Edema Macular.</source><year>2021</year><comment>Available online: <ext-link xlink:href="https://serv.es/" ext-link-type="uri">https://serv.es/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-06">(accessed on 6 March 2024)</date-in-citation></element-citation></ref><ref id="B15-pharmacy-13-00068"><label>15.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Sociedad Espa&#x000f1;ola de Retina y V&#x000ed;treo (SERV)</collab>
</person-group><article-title>Gu&#x000ed;as de Pr&#x000e1;ctica Cl&#x000ed;nica y Monograf&#x000ed;as. Gu&#x000ed;a 1: Tratamiento de la DMAE Exudativa</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://serv.es/" ext-link-type="uri">https://serv.es/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-06">(accessed on 6 March 2024)</date-in-citation></element-citation></ref><ref id="B16-pharmacy-13-00068"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mantovani</surname><given-names>L.G.</given-names></name>
<name><surname>Monzini</surname><given-names>M.S.</given-names></name>
<name><surname>Mannucci</surname><given-names>P.M.</given-names></name>
<name><surname>Scalone</surname><given-names>L.</given-names></name>
<name><surname>Villa</surname><given-names>M.</given-names></name>
<name><surname>Gringeri</surname><given-names>A.</given-names></name>
<collab>Conan Study Group</collab>
</person-group><article-title>Differences between patients&#x02019;, physicians&#x02019; and pharmacists&#x02019; preferences for treatment products in haemophilia: A discrete choice experiment</article-title><source>Haemophilia</source><year>2005</year><volume>11</volume><fpage>589</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2516.2005.01159.x</pub-id><pub-id pub-id-type="pmid">16236108</pub-id>
</element-citation></ref><ref id="B17-pharmacy-13-00068"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Andr&#x000e9;s-Nogales</surname><given-names>F.</given-names></name>
<name><surname>Casado</surname><given-names>M.&#x000c1;.</given-names></name>
<name><surname>Trillo</surname><given-names>J.L.</given-names></name>
<name><surname>Ruiz-Moreno</surname><given-names>J.M.</given-names></name>
<name><surname>Mart&#x000ed;nez-Sesmero</surname><given-names>J.M.</given-names></name>
<name><surname>Peralta</surname><given-names>G.</given-names></name>
<name><surname>Poveda</surname><given-names>J.L.</given-names></name>
<name><surname>Ortiz</surname><given-names>P.</given-names></name>
<name><surname>Ignacio</surname><given-names>E.</given-names></name>
<name><surname>Zarranz-Ventura</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study</article-title><source>Pharmacoecon. Open</source><year>2020</year><volume>4</volume><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1007/s41669-020-00201-2</pub-id><pub-id pub-id-type="pmid">32100249</pub-id>
</element-citation></ref><ref id="B18-pharmacy-13-00068"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mart&#x000ed;nez-L&#x000f3;pez</surname><given-names>I.</given-names></name>
<name><surname>Maurino</surname><given-names>J.</given-names></name>
<name><surname>Sanmart&#x000ed;n-Fenollera</surname><given-names>P.</given-names></name>
<name><surname>Onta&#x000f1;on-Nasarre</surname><given-names>A.</given-names></name>
<name><surname>Santiago-P&#x000e9;rez</surname><given-names>A.</given-names></name>
<name><surname>Moya-Carmona</surname><given-names>I.</given-names></name>
<name><surname>Garc&#x000ed;a-Collado</surname><given-names>C.G.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Del Olmo</surname><given-names>R.</given-names></name>
<name><surname>Garc&#x000ed;a-Arcelay</surname><given-names>E.</given-names></name>
<name><surname>Sarmiento</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Assessing Pharmacists&#x02019; Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis</article-title><source>Pharmacy</source><year>2020</year><volume>8</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.3390/pharmacy8020061</pub-id><pub-id pub-id-type="pmid">32272683</pub-id>
</element-citation></ref><ref id="B19-pharmacy-13-00068"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luce</surname><given-names>R.D.</given-names></name>
<name><surname>Tukey</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Simultaneous conjoint measurement: A new type of fundamental measurement</article-title><source>J. Math. Psychol.</source><year>1964</year><volume>1</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/0022-2496(64)90015-X</pub-id></element-citation></ref><ref id="B20-pharmacy-13-00068"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McFadden</surname><given-names>D.</given-names></name>
</person-group><article-title>The choice theory approach to market research</article-title><source>Mark. Sci.</source><year>1986</year><volume>5</volume><fpage>275</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1287/mksc.5.4.275</pub-id></element-citation></ref><ref id="B21-pharmacy-13-00068"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farley</surname><given-names>K.</given-names></name>
<name><surname>Thompson</surname><given-names>C.</given-names></name>
<name><surname>Hanbury</surname><given-names>A.</given-names></name>
<name><surname>Chambers</surname><given-names>D.</given-names></name>
</person-group><article-title>Exploring the feasibility of Conjoint Analysis as a tool for prioritizing innovations for implementation</article-title><source>Implement. Sci.</source><year>2013</year><volume>8</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/1748-5908-8-56</pub-id><pub-id pub-id-type="pmid">23714429</pub-id>
</element-citation></ref><ref id="B22-pharmacy-13-00068"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Webb</surname><given-names>E.J.D.</given-names></name>
<name><surname>Meads</surname><given-names>D.</given-names></name>
<name><surname>Eskyte</surname><given-names>I.</given-names></name>
<name><surname>King</surname><given-names>N.</given-names></name>
<name><surname>Dracup</surname><given-names>N.</given-names></name>
<name><surname>Chataway</surname><given-names>J.</given-names></name>
<name><surname>Ford</surname><given-names>H.L.</given-names></name>
<name><surname>Marti</surname><given-names>J.</given-names></name>
<name><surname>Pavitt</surname><given-names>S.H.</given-names></name>
<name><surname>Schmierer</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis</article-title><source>Patient.</source><year>2018</year><volume>11</volume><fpage>391</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1007/s40271-017-0296-y</pub-id><pub-id pub-id-type="pmid">29313265</pub-id>
</element-citation></ref><ref id="B23-pharmacy-13-00068"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Omari</surname><given-names>B.</given-names></name>
<name><surname>Farhat</surname><given-names>J.</given-names></name>
<name><surname>Ershaid</surname><given-names>M.</given-names></name>
</person-group><article-title>Conjoint Analysis: A Research Method to Study Patients&#x02019; Preferences and Personalize Care</article-title><source>J. Pers. Med.</source><year>2022</year><volume>12</volume><elocation-id>274</elocation-id><pub-id pub-id-type="doi">10.3390/jpm12020274</pub-id><pub-id pub-id-type="pmid">35207762</pub-id>
</element-citation></ref><ref id="B24-pharmacy-13-00068"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Del R&#x000ed;o-Mu&#x000f1;oz</surname><given-names>B.</given-names></name>
<name><surname>Azanza-Munarriz</surname><given-names>C.</given-names></name>
<name><surname>Becerril-R&#x000ed;os</surname><given-names>N.</given-names></name>
<name><surname>Goicochea-Brice&#x000f1;o</surname><given-names>H.</given-names></name>
<name><surname>Horno</surname><given-names>R.</given-names></name>
<name><surname>Lend&#x000ed;nez-Mesa</surname><given-names>A.</given-names></name>
<name><surname>S&#x000e1;nchez-Franco</surname><given-names>C.</given-names></name>
<name><surname>Sarmiento</surname><given-names>M.</given-names></name>
<name><surname>Bueno-Gil</surname><given-names>G.</given-names></name>
<name><surname>Medrano</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Preferences Toward Attributes of Disease-Modifying Therapies: The Role of Nurses in Multiple Sclerosis Care</article-title><source>J. Neurosci. Nurs.</source><year>2022</year><volume>54</volume><fpage>220</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1097/JNN.0000000000000661</pub-id><pub-id pub-id-type="pmid">35700983</pub-id>
</element-citation></ref><ref id="B25-pharmacy-13-00068"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heier</surname><given-names>J.S.</given-names></name>
<name><surname>Khanani</surname><given-names>A.M.</given-names></name>
<name><surname>Quezada Ruiz</surname><given-names>C.</given-names></name>
<name><surname>Basu</surname><given-names>K.</given-names></name>
<name><surname>Ferrone</surname><given-names>P.J.</given-names></name>
<name><surname>Brittain</surname><given-names>C.</given-names></name>
<name><surname>Figueroa</surname><given-names>M.S.</given-names></name>
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>Holz</surname><given-names>F.G.</given-names></name>
<name><surname>Patel</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>729</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00010-1</pub-id><pub-id pub-id-type="pmid">35085502</pub-id>
</element-citation></ref><ref id="B26-pharmacy-13-00068"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mart&#x000ed;nez-Castillo</surname><given-names>R.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Gallardo</surname><given-names>C.</given-names></name>
<name><surname>Mu&#x000f1;oz-&#x000c1;vila</surname><given-names>J.I.</given-names></name>
<name><surname>Font</surname><given-names>P.</given-names></name>
<name><surname>Villalba-Gonz&#x000e1;lez</surname><given-names>M.</given-names></name>
<name><surname>Stoikow</surname><given-names>I.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Choquet de Isla</surname><given-names>I.</given-names></name>
<name><surname>Pugliese</surname><given-names>F.</given-names></name>
<name><surname>Anaya-Alaminos</surname><given-names>R.</given-names></name>
<name><surname>Garc&#x000ed;a-Serrano</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group><article-title>Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>160</volume><elocation-id>114368</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114368</pub-id><pub-id pub-id-type="pmid">36753959</pub-id>
</element-citation></ref><ref id="B27-pharmacy-13-00068"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Rao</surname><given-names>V.R.</given-names></name>
</person-group><article-title>Conjoint analysis</article-title><source>Wiley International Encyclopedia of Marketing</source><publisher-name>John Wiley &#x00026; Sons</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2010</year></element-citation></ref><ref id="B28-pharmacy-13-00068"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coast</surname><given-names>J.</given-names></name>
<name><surname>Flynn</surname><given-names>T.N.</given-names></name>
<name><surname>Salisbury</surname><given-names>C.</given-names></name>
<name><surname>Louviere</surname><given-names>J.</given-names></name>
<name><surname>Peters</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Maximising responses to discrete choice experiments: A randomised trial</article-title><source>Appl. Health Econ. Health Policy</source><year>2006</year><volume>5</volume><fpage>249</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.2165/00148365-200605040-00006</pub-id><pub-id pub-id-type="pmid">17249841</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmacy-13-00068-f001"><label>Figure 1</label><caption><p>Mean (SD) ranking of different scenarios: (<bold>a</bold>) nAMD; (<bold>b</bold>) DME. DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; SD, standard deviation.</p></caption><graphic xlink:href="pharmacy-13-00068-g001" position="float"/></fig><fig position="float" id="pharmacy-13-00068-f002"><label>Figure 2</label><caption><p>Mean ranking of different scenarios by clinical experience: (<bold>a</bold>) nAMD; (<bold>b</bold>) DME. DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration.</p></caption><graphic xlink:href="pharmacy-13-00068-g002" position="float"/></fig><table-wrap position="float" id="pharmacy-13-00068-t001"><object-id pub-id-type="pii">pharmacy-13-00068-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic and professional practice characteristics of the sample.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total Sample<break/>(<italic toggle="yes">n</italic> = 91) *</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="center" valign="middle" rowspan="1" colspan="1">39.2 (10.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex, female, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (60.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Years as a HP, mean (SD) (valid <italic toggle="yes">n</italic> = 89)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.6 (8.3)</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Years of managing patients with intravitreal treatments for nAMD/DME, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;1 year</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (8.8%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02265;1 year</td><td align="center" valign="middle" rowspan="1" colspan="1">83 (91.2%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number of years of experience managing intravitreal treatments, mean (SD) (valid <italic toggle="yes">n</italic> = 83)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.4 (5.0)</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Level of clinical experience according to years of experience managing intravitreal treatments (quartile definition)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Some experience (&#x02264;5 years)</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (52.7%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Broad experience (&#x0003e;5 years)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (47.3%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Participation in nAMD/DME clinical trials, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (13.2%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Author or co-author of scientific publications, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (48.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Participation in a pharmacy commission for the evaluation of medicines, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">73 (80.2%)</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Current position</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Head of service</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (17.6%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Specialist pharmacist</td><td align="center" valign="middle" rowspan="1" colspan="1">63 (69.2%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Pharmacy resident</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (13.2%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pharmacist profile, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Manufacturer/sterile area</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (48.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Logistic area</td><td align="center" valign="middle" rowspan="1" colspan="1">47 (51.6%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Type of hospital, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Regional hospital</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (27.5%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;University hospital</td><td align="center" valign="middle" rowspan="1" colspan="1">66 (72.5%)</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Number of treatments prepared for intravitreal administration in a month, mean (SD)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;For nAMD (valid <italic toggle="yes">n</italic> = 87)</td><td align="center" valign="middle" rowspan="1" colspan="1">215.7 (232.8)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;For DME (valid <italic toggle="yes">n</italic> = 86)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.0 (94.2)</td></tr></tbody></table><table-wrap-foot><fn><p>* Unless otherwise specified. DME, diabetic macular edema; HP, hospital pharmacist; nAMD, neovascular age-related macular degeneration; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmacy-13-00068-t002"><object-id pub-id-type="pii">pharmacy-13-00068-t002_Table 2</object-id><label>Table 2</label><caption><p>Utility scores and importance assigned to each attribute and level.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Variable</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Utility Estimation</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">nAMD (<italic toggle="yes">n</italic> = 91)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">DME (<italic toggle="yes">n</italic> = 91)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nAMD<break/>(<italic toggle="yes">n</italic> = 91)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DME<break/>(<italic toggle="yes">n</italic> = 91)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Importance (Relative)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Importance (Averaged)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Importance (Relative)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Importance (Averaged)</th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="middle" colspan="1">BCVA</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;15 letters </td><td align="center" valign="middle" rowspan="1" colspan="1">1.294</td><td align="center" valign="middle" rowspan="1" colspan="1">1.266</td><td rowspan="2" align="center" valign="middle" colspan="1">38.6%</td><td rowspan="2" align="center" valign="middle" colspan="1">36.5%</td><td rowspan="2" align="center" valign="middle" colspan="1">44.6%</td><td rowspan="2" align="center" valign="middle" colspan="1">34.5%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;15 letters</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.294</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.266</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Ocular AE</td><td align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Severe but less<break/>frequent AE</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">&#x02212;0.915</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">&#x02212;0.723</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">27.3%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">27.7%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">25.5%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">25.1%</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild but more <break/>frequent AE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.915</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.723</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Annual drug cost</td><td align="left" valign="middle" rowspan="1" colspan="1">Increase</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.547</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.508</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">16.3%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15.3%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">17.9%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15.4%</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No effect/decrease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.547</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.508</td></tr><tr><td rowspan="3" align="left" valign="middle" colspan="1">Available presentation</td><td align="left" valign="middle" rowspan="1" colspan="1">Prefilled syringe</td><td align="center" valign="middle" rowspan="1" colspan="1">0.371</td><td align="center" valign="middle" rowspan="1" colspan="1">0.234</td><td rowspan="3" align="center" valign="middle" colspan="1">11.1%</td><td rowspan="3" align="center" valign="middle" colspan="1">13.3%</td><td rowspan="3" align="center" valign="middle" colspan="1">7.3%</td><td rowspan="3" align="center" valign="middle" colspan="1">15.5%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vial</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.371</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.183</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Implant</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.051</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">MoA</td><td align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">MoA with more<break/>spacing between doses</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.225</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.135</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">6.7%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">7.3%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">4.8%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">9.5%</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MoA with less spacing between doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.225</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.135</td></tr></tbody></table><table-wrap-foot><fn><p>AE, adverse event; BCVA, best corrected visual acuity; DME, diabetic macular edema; MoA, mechanism of action; nAMD, neovascular age-related macular degeneration.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmacy-13-00068-t003"><object-id pub-id-type="pii">pharmacy-13-00068-t003_Table 3</object-id><label>Table 3</label><caption><p>Utility scores and importance assigned to each attribute and level by clinical experience.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Variable</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Utility Estimation</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Importance (Relative)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Importance (Averaged)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Some<break/>Experience<break/>(<italic toggle="yes">n</italic> = 48)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad<break/>Experience<break/>(<italic toggle="yes">n</italic> = 43)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Some<break/>Experience<break/>(<italic toggle="yes">n</italic> = 48)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad<break/>Experience<break/>(<italic toggle="yes">n</italic> = 43)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Some<break/>Experience<break/>(<italic toggle="yes">n</italic> = 48)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad<break/>Experience<break/>(<italic toggle="yes">n</italic> = 43)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>nAMD</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="left" valign="middle" colspan="1">BCVA</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;15 letters</td><td align="center" valign="middle" rowspan="1" colspan="1">1.385</td><td align="center" valign="middle" rowspan="1" colspan="1">1.192</td><td rowspan="2" align="center" valign="middle" colspan="1">41.1%</td><td rowspan="2" align="center" valign="middle" colspan="1">35.8%</td><td rowspan="2" align="center" valign="middle" colspan="1">38.5%</td><td rowspan="2" align="center" valign="middle" colspan="1">34.3%</td><td rowspan="2" align="center" valign="middle" colspan="1">0.2826</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;15 letters</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.385</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.192</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Ocular AE</td><td align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Severe but less<break/>frequent AE</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">&#x02212;0.849</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">&#x02212;0.988</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">25.2%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">29.7%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">25.8%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">29.8%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">0.3132</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild but more <break/>frequent AE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.849</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.988</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Annual drug cost</td><td align="left" valign="middle" rowspan="1" colspan="1">Increase</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.536</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.558</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15.9%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">16.8%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">14.7%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15.9%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.6368</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No effect/decrease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.536</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.558</td></tr><tr><td rowspan="2" align="left" valign="middle" colspan="1">Available presentation</td><td align="left" valign="middle" rowspan="1" colspan="1">Prefilled syringe</td><td align="center" valign="middle" rowspan="1" colspan="1">0.458</td><td align="center" valign="middle" rowspan="1" colspan="1">0.273</td><td rowspan="2" align="center" valign="middle" colspan="1">13.6%</td><td rowspan="2" align="center" valign="middle" colspan="1">8.2%</td><td rowspan="2" align="center" valign="middle" colspan="1">15.5%</td><td rowspan="2" align="center" valign="middle" colspan="1">10.8%</td><td rowspan="2" align="center" valign="middle" colspan="1">0.1169</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vial</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.458</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.273</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">MoA</td><td align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">MoA with more<break/>spacing between doses</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.141</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.320</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">4.2%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">9.6%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">5.5%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">9.3%</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">0.0253</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MoA with less spacing between doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.141</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.320</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>DME</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">BCVA</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;15 letters </td><td align="center" valign="middle" rowspan="1" colspan="1">1.245</td><td align="center" valign="middle" rowspan="1" colspan="1">1.291</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">42.5%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">46.0%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">33.0%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">36.2%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.4000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;15 letters</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.245</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.291</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Ocular AE</td><td align="left" valign="middle" rowspan="1" colspan="1">Severe but less<break/>frequent AE</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.646</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.808</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">22.1%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">28.8%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">24.3%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">26.0%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.6592</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild but more <break/>frequent AE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.646</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.808</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Annual drug cost</td><td align="left" valign="middle" rowspan="1" colspan="1">Increase</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.521</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.494</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">17.8%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">17.6%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">16.5%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">14.2%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.3891</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No effect/decrease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.521</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.494</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Available presentation</td><td align="left" valign="middle" rowspan="1" colspan="1">Prefilled syringe</td><td align="center" valign="middle" rowspan="1" colspan="1">0.354</td><td align="center" valign="middle" rowspan="1" colspan="1">0.101</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">12.2%</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.8%</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">16.4%</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">14.5%</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.5565</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vial</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.359</td><td align="center" valign="middle" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Implant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.114</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">MoA</td><td align="left" valign="middle" rowspan="1" colspan="1">MoA with more<break/>spacing between doses</td><td align="center" valign="middle" rowspan="1" colspan="1">0.161</td><td align="center" valign="middle" rowspan="1" colspan="1">0.105</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5.5%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.7%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">9.8%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">9.2%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.7549</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MoA with less spacing between doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.161</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.105</td></tr></tbody></table><table-wrap-foot><fn><p>AE, adverse event; BCVA, best corrected visual acuity; DME, diabetic macular edema; MoA, mechanism of action; nAMD, neovascular age-related macular degeneration.</p></fn></table-wrap-foot></table-wrap></floats-group></article>